### **Overview** **Granules India Ltd.** is a **vertically integrated, science-led pharmaceutical company** headquartered in Hyderabad, India, and founded in 1991. The company has evolved from a bulk paracetamol API manufacturer into a **global player across the complete pharmaceutical value chain**, producing **Active Pharmaceutical Ingredients (APIs)**, **Pharmaceutical Formulation Intermediates (PFIs)**, and **Finished Dosages (FDs)**. It operates 11 manufacturing facilities—**8 in India, 2 in the U.S., and 1 in Switzerland**—and serves over **300 customers in more than 80 countries**, with a strong presence in North America, Europe, Latin America, and emerging markets. The company holds regulatory approvals from **US FDA, EU GMP, WHO GMP, Swissmedic**, and other global agencies, reflecting its commitment to compliance and quality. It has established subsidiaries across geographies, including **Granules Pharmaceuticals Inc. (GPI)** in the U.S. and **Ascelis Peptides**, the dedicated platform for its entry into high-growth peptide therapeutics. --- ### **Core Business Segments & Revenue Mix** Granules operates across three core verticals: 1. **APIs (Active Pharmaceutical Ingredients)**: Includes high-volume molecules such as Paracetamol, Metformin, Ibuprofen, Guaifenesin, and Methocarbamol. 2. **PFIs (Pharmaceutical Formulation Intermediates)**: Offers cost-efficient, drum-to-hopper solutions to global pharma firms. 3. **FDs (Finished Dosages)**: Includes complex oral solids, ER/XR tablets, chewables, caplets, MUPS, and oral solutions. #### **Revenue Breakdown (FY2024–25):** - **Finished Dosages (FD)**: ₹4,438 million (~77% of total revenue) - **APIs**: ₹34,535 million - **PFIs**: ₹2,082 million - **Geographic Revenue Mix**: - **North America**: 77% (Primary market, U.S.-driven) - **India**: 10% - **Latin America**: 5% - **Europe**: 5% - **Rest of World (RoW)**: 3% FD has become the dominant revenue segment, rising from 65% in FY2023–24 to 77% in FY2024–25, reflecting successful vertical integration and strategic portfolio optimization. --- ### **Strategic Growth Drivers & Transformation** Granules is undergoing a **strategic transformation** from a generic API-focused manufacturer to a **differentiated, innovation-led global drug developer and contract service provider**. #### **Key Growth Pillars:** 1. **CNS/ADHD Leadership in the U.S.** - The U.S.-based **GPI (Granules Pharmaceuticals Inc.)** is a market leader in **controlled substances for ADHD**, including **Adderall IR/XR**, **Dexmethylphenidate**, and **Methylphenidate**. - Received FDA approval for **lisdexamfetamine chewable tablets and capsules**, launched commercially. - Offers differentiated dosage forms: abuse-deterrent, pediatric-friendly, chewables — with limited competition. 2. **Oncology Expansion** - The **Unit V facility in Visakhapatnam** is a dedicated **oncology API and OSD plant**. - Pipeline includes **7–10 oncology products**, with filings underway in the U.S. (ANDA) and EU (MAA). - Focus on **day-one and day-181 launches** with complex generics and **New Chemical Entities (NCEs)**. 3. **Entry into Peptide Therapeutics & CDMO Space** - **Acquisition of Senn Chemicals AG (Switzerland)** in 2025 enabled a strategic pivot into **peptides, oligonucleotides, and peptide-drug conjugates**. - Launch of **Ascelis Peptides**, a wholly-owned global subsidiary, provides **end-to-end CDMO services**. - Targeting **high-growth markets**: **GLP-1 receptor agonists** (e.g., semaglutide, tirzepatide) for diabetes and obesity, where the global market is projected to surpass **$130 billion by 2030**. - Capabilities in **liquid-phase (LPPS)** and **solid-phase peptide synthesis (SPPS)**, supported by Swiss expertise and Indian scale. 4. **Vertical Integration & Value-Chain Upgrades** - Backward integration into **key starting materials (KSMs)** and **intermediates** (e.g., PAP, DCDA) via **CZRO initiative**. - Green chemistry platforms using **biocatalysis, fermentation, and continuous manufacturing**. - Over **60% of new products** are now vertically integrated. 5. **Commercialization of Genome Valley Facility** - **Granules Life Sciences (GLS)**: New greenfield formulation site in Hyderabad. - **Full capacity of 10 billion dosage units** expected by FY2026. - Already producing monograph products; awaiting FDA/EU inspections for prescription product commercialization (expected Q2 FY26). - Equipped with advanced tech: **Wurster coaters, MUPS lines, Sensum inspection, Bohle coater**. --- ### **Innovation & R&D Strategy** Granules operates a **global R&D network** with over **400 scientists** across: - **Genome Valley, Hyderabad** – Integrated Product Development Center (170+ scientists) - **Pune Innovation Hub** – Backward integration & green chemistry - **Pragathi Nagar, Hyderabad** – Center of Excellence (controlled substances, KSMs) - **Chantilly, Virginia, U.S.** – Formulation R&D (GPI) - **Zurich, Switzerland** – Peptide R&D via Senn Chemicals/Ascelis #### **R&D Focus Areas:** - **Controlled substances (Schedule II)**: Internal development of **lisdexamfetamine, oxybates, and Ruxolitinib**. - **Complex dosage forms**: MUPS, bilayer tablets, abuse-deterrent, pediatric-friendly. - **Metabolic disorders**: **Gliptins (DPP-4 inhibitors)**, **gliflozins (SGLT2 inhibitors)**. - **Oncology**: JAK inhibitors, targeted therapies. - **Next-gen modalities**: Peptides (including generic GLP-1s), oligonucleotides, PDCs. #### **R&D Expenditure:** - FY2024–25: ₹2,377 million (~5.3% of revenue), up from 4.4%. - Target: **>6% of revenue**. - Filed **119 patent applications** globally, with **10 granted**. - Filed **85 ANDAs** in the U.S., with **68 approved** and **17 under review**; **20 filed in Europe**. --- ### **Manufacturing & Global Footprint** - **11 Manufacturing Sites**: - **India (8)**: Bonthapally (API), Jeedimetla (API/PFI), Gagillapur (PFI/FD), Visakhapatnam (Oncology—Unit IV and Unit V), Genome Valley (FD). - **U.S. (2)**: Chantilly, Virginia (GPI: R&D, formulation, controlled substances, packaging). - **Switzerland (1)**: Dielsdorf (Senn Chemicals: peptide synthesis). - **Regulatory Approvals**: US FDA, EU GMP, WHO GMP, Swissmedic, KFDA. - **Annual Capacities**: - **API**: ~40,000 TPA - **FD**: Over 40 billion units - **PFI**: 6-ton batch capacity (one of the largest globally) Facilities are supported by **automation, IoT-enabled predictive maintenance, and real-time dashboards**, improving OEE by 8–12% and reducing downtime by 40%. --- ### **Sustainability & ESG Initiatives** Granules has taken a **leadership role in green pharmaceutical manufacturing**, recognized in the **2024 CDP Supplier Engagement A-List**. #### **CZRO Initiative (Greenko Partnership):** - Aims to create the **world’s first integrated green pharmaceutical zone** in **Kakinada, Andhra Pradesh**. - Uses **carbon-free energy (green hydrogen, ammonia)** to produce **paracetamol and metformin** with near **Net Zero** cradle-to-gate carbon footprint. - Targets **self-reliance** in **KSMs (DCDA, PAP)**, with pilot plants in Vizag (completed by FY24) and commercial units by end-FY25. - **Science-Based Targets (SBTi-validated)**: Net Zero by 2050 aligned with 1.5°C climate pathway. - **Circular economy model**: Waste from one process reused as input in another, minimizing emissions. --- ### **Recent Strategic Milestones (2024–2025)** - **Acquisition of Senn Chemicals AG** (Swiss CDMO) – Entry into peptide CDMO and therapeutics. - **Launch of Ascelis Peptides** – Dedicated platform for peptides, oligos, and PDCs. - **Phase I of GLS Genome Valley** commercially operational (2.5 B doses). - **FDA approval for lisdexamfetamine chewables and ER tablets**. - **API validation and DMF filing** for lisdexamfetamine in process (Q1 FY26). - **10 new oncology products** under development, with first filing submitted in U.S. and EU. - **Expansion of European footprint**: 3 dossiers filed in EU, aiming for commercialization by early 2026.